M AGLIETTA
Aglietta, Massimo
VIAF ID: 280400665 (Personal)
Permalink: http://viaf.org/viaf/280400665
Preferred Forms
-
100 1 _
‡a
Aglietta, Massimo
-
100 1 _ ‡a Aglietta, Massimo
-
100 1 _
‡a
Aglietta, Massimo
-
100 1 _
‡a
Aglietta, Massimo
-
100 1 _
‡a
Aglietta, Massimo
-
100 1 _ ‡a Aglietta, Massimo
-
100 0 _
‡a
M AGLIETTA
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Imaging tumor response to therapy, c2012: |
|
| Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl |
|
| MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors |
|
| Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
|
| Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer |
|
| Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies |
|
| Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells |
|
| Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases |
|
| Next generation immune-checkpoints for cancer therapy. |
|
| Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas |
|
| Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis |
|
| Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival |
|
| Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). |
|
| PARP Inhibitors in Ovarian Cancer. |
|
| PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models |
|
| Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives |
|
| Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen |
|
| A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study. |
|
| A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer |
|
| Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells |
|
| A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. |
|
| Poor prognosis osteosarcoma: new therapeutic approach. |
|
| Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. |
|
| Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer |
|
| Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. |
|
| A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. |
|
| Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
|
| The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer |
|
| Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature. |
|
| Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). |
|
| Prostaglandins and myelopoiesis: effect of prostaglandin E1 on normal and chronic myeloid leukemia colony forming cells (CFU-GM) subpopulations |
|
| Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018 |
|
| Rationale for the use of metronomic chemotherapy in gastrointestinal cancer |
|
| Recent advances in the development of breast cancer vaccines |
|
| Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. |
|
| Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions |
|
| Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer |
|
| Responsiveness to prostaglandin E1 of different subtypes of normal and pathological committed granulomonopoietic precursors. |
|
| The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma |
|
| The role of c-Mpl ligands in the expansion of cord blood hematopoietic progenitors |
|
| Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study |
|
| Role of interferon in melanoma: old hopes and new perspectives. |
|
| The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. |
|
| Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report |
|
| Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses |
|
| Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. |
|
| Selected highlights from the 26th San Antonio Breast Cancer Symposium. December 3-6, 2003, San Antonio, TX, USA |
|
| Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
|
| Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions. |
|
| Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease |
|
| Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. |
|
| Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways |
|
| Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report |
|
| Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect |
|
| Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. |
|
| Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. |
|
| Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma |
|
| Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors |
|
| TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. |
|
| Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group |
|
| Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. |
|
| Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. |
|
| Translocation of the c-myc oncogene 3′ to the immunoglobin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma |
|
| Translocation-related sarcomas. |
|
| Transmission of hepatitis C via blood splash into conjunctiva |
|
| Trastuzumab beyond disease progression: case closed? |
|
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. |
|
| Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial |
|
| Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison |
|
| Treating breast cancer with cell-based approaches: an overview. |
|
| Treatment of metastatic melanoma: a multidisciplinary approach |
|
| Underuse of anthracyclines in women with HER-2+ advanced breast cancer |
|
| Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan |
|
| Vasculogenic potential of long term repopulating cord blood progenitors. |
|
| Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. |
|
| Veliparib: a new therapeutic option in ovarian cancer? |
|
| What can we learn from the ZOOM trial?--Authors' reply |
|
| Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. |
|
